Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. AJOVY
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

AJOVY

Medicine - Posted on Apr 11 2025
Active substance (DCI)
  • frémanezumab
history (3)
  • 4/9/25

    AJOVY (frémanezumab) - Migraine

    Modification des conditions de l'inscription L'essentiel Avis favorable au remboursement uniquement chez les « patients adul...
    CAV :
    54321
    icône flèche
  • 9/14/22

    AJOVY (frémanezumab)

    Key points Approved for reimbursement only for adult patients suffering from severe migraine with at least 8 migraine days p...
    CAV :
    54321
    icône flèche
  • 9/16/20

    AJOVY

    Key points Favourable opinion for reimbursement in adult patients with severe migraine who have at least 8 migraine days per...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • N02CD03
Manufacturer
TEVA SANTE
Presentation

AJOVY 225 mg, solution injectable en seringue préremplie
1 seringue préremplie de 1,5 ml de solution (CIP : 34009 301 745 9 3)

AJOVY 225 mg, solution injectable en stylo prérempli
1 stylo prérempli de 1,5 ml de solution (CIP : 34009 301 987 4 2)

All our publications
    Central nervous system diseases Drug therapy Pain - Inflammation

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
7Aytc5pv7NhK30D2